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Background: Acute kidney injury occurring after kidney transplantation frequently leads to 
delayed graft function with detrimental long-term effects on graft survival. Neutrophil gelati-
nase-associated lipocalin (NGAL) has been validated as a biomarker for posttransplant acute 
kidney injury. This observational study aimed to assess the effectiveness of urinary NGAL as 
a predictive marker of delayed graft function.
Materials and methods: Forty-three consecutive patients who received renal transplant were 
included in the study. Urine samples were collected before transplant (if available) and at days 
1, 3, 7, 14, and 30 after transplant, and urinary NGAL levels were quantified by enzyme-linked 
immunosorbent assay.
Results: Urinary NGAL progressively decreased after transplant in patients with both delayed 
and immediate graft function. However, urinary NGAL concentration remained significantly 
higher in the presence of delayed graft function in the first 14 days after transplant. The area 
under the receiver operating characteristic curve showed that the ability of urinary NGAL to 
predict delayed graft function was accurate at 1st and 3rd days after transplant.
Conclusion: The relative decrease of urinary NGAL concentration rather than its absolute 
value may be relevant to predict delayed graft function after renal transplant. In particular, uri-
nary NGAL area under the curve for 3 days seems to be a more valuable parameter of decision 
making in the early posttransplant period.
Keywords: area under the curve, delayed graft function, immediate graft function, kidney 
transplant, NGAL, acute kidney injury
Introduction
Acute kidney injury (AKI) occurring after renal transplantation frequently progresses 
to delayed graft function (DGF). Poor kidney function in the first week of graft life 
is detrimental to allograft longevity and may cause poor graft survival, acute rejec-
tion, and impaired renal function.1,2 In addition to DGF, even mild to moderate post-
transplant graft dysfunction, namely, slow graft functions, has been proven to affect 
long-term graft survival.3,4 DGF prevalence is constantly growing, mostly due to the 
use of organs recovered from expanded criteria donors and prolonged cold ischemia 
times.5–7 Validation of immune or nonimmune biomarkers potentially able to immedi-
ately predict AKI after transplant could improve the possibility of a timely diagnosis 
and reduce the risk of DGF.8
In the last few years, great interest has been focused on neutrophil gelatinase-
associated lipocalin (NGAL), a promising biomarker for the prediction of kidney 
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injury in the early posttransplant period. The advantage 
of NGAL lies in the fact that kidney epithelia express and 
excrete large quantities of NGAL into urine immediately 
after ischemia–reperfusion injury, anticipating the rise of 
serum creatinine by several hours. It has been reported 
that increased local production of NGAL by the tubular 
epithelium of DGF kidneys contributes to the high circu-
lating and urine levels, reflecting the ischemia/reperfusion 
stress applied to the transplanted kidney before organ 
withdrawal, during the storage period, and during succes-
sive reperfusion.9–11
NGAL is a 25 kDa protein belonging to the lipocalin 
superfamily. It was initially found in activated neutrophils; 
however, many other cells, like kidney tubular cells, may 
produce it in response to various insults.12
Both urinary NGAL and plasma NGAL have been 
extensively investigated as reliable biomarkers in several 
clinical conditions, including cardiac surgery-related AKI, 
poor renal function in very low birth weight infants, criti-
cally ill patients, and DGF in kidney transplantation.13–16 In 
addition, we have recently described the ability of NGAL to 
induce immune tolerance by upregulating human leukocyte 
antigen (HLA-G) expression and expansion of  T-regulatory 
cells in healthy donors, providing the basis for further stud-
ies to evaluate its possible role in immunomodulation and 
tolerance induction in transplant recipients.17
This mounting evidence led to evaluate the role of 
NGAL after kidney transplant. Plasma levels of NGAL 
rapidly decrease when the renal function is restored. This 
may be due to lower NGAL production, negative balance 
between extrarenal NGAL synthesis and renal washout, or 
renal uptake modification. NGAL is physiologically filtered 
by the glomerulus and almost completely reabsorbed in 
the proximal tubule.14 After ischemia–reperfusion injury 
in transplanted kidneys, tubular reabsorption may still 
be impaired even in the presence of normal glomerular 
filtration rate (GFR) and immediate graft function (IGF). 
Therefore, it is crucial to promptly discriminate early from 
DGF. To this purpose, here, we propose a prospective 
observational study aimed to assess the effectiveness of 
urinary NGAL as a predictive marker of DGF after kidney 
transplantation.
Materials and methods
Study design and patients
This is a prospective observational study on 43 consecutive 
patients who received renal transplantation from deceased 
donors at our Kidney Transplant Center from February 2009 
to May 2010.
All of them were treated with the same immunosuppres-
sive therapy based on steroids (methylprednisolone 500 mg 
at day 0, 250 mg at day 1, 125 mg at day 2, 80 mg at day 3, 
and tapered until the final level of 5 mg per day was reached), 
tacrolimus (5–8 ng/mL), and mycophenolic acid (1440 mg 
until day 14, then 720 mg). The following demographic, clini-
cal, and transplant-related characteristics of all the patients 
were collected: sex, recipient age, donor age, cold ischemia 
interval, number of HLA mismatches, time on dialysis prior 
to transplantation, dialysis modality, primary renal disease, 
and incidence of posttransplant complications.
At 2 years after transplantation, estimated GFR (eGFR) 
was calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation, as a follow-up 
routine analysis.
To assess the predictive value of urinary NGAL in pre-
dicting DGF, the renal transplant recipients included in the 
study were divided into 2 groups: patients with DGF (DGF 
group, n=18) versus patients with IGF (IGF group, n=25). 
DGF was defined as the need for dialysis within the first 
7 days after transplantation.
The study protocol was approved by the Independent 
Ethics Committee of the University Hospital of Bologna 
“S. Orsola-Malpighi”, and a written informed consent was 
obtained from all the patients. The study was conducted 
according to the Helsinki Declaration.
Urine collection and enzyme-linked 
immunosorbent assay (ELISA)
Urine samples were collected before transplantation (if avail-
able) and at day 1, 3, 7, 14, and 30 after transplantation (T0, 
T1, T2, T3, T4, and T5, respectively). Urine samples were 
centrifuged at 1500 rpm for 10 min, and the supernatants 
were stored at −20°C until analysis.
All the samples were analyzed in the laboratory of our 
unit. Urinary levels of NGAL were assayed using a com-
mercially available ELISA test, according to manufacturer’s 
instructions (NGAL ELISA Kit 036; BioPorto Diagnostics, 
Grusbakken, Denmark). Briefly, the assay was performed on 
microplates coated with monoclonal antibody against human 
NGAL. Samples and calibrators were quantified in the same 
microplate. Urinary NGAL was detected with a colorimetric 
reaction by measuring the absorbance at 450 nm and its 
concentration was derived from the calibration curve and 
expressed in ng/mL. The sensitivity limit (minimum detect-
able concentration) was 1.4 pg/mL.  Intra-assay  variation was 
determined by measurement of NGAL in 2 urine samples 
with 6–8 replicates, and the coefficient of variation was as 
follows: urine A 14% and urine B 7%. Interassay variation 
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was determined by measurement of NGAL in 2 diluted urine 
samples with 2–8 replicates in 2–4 separate assays. The fol-
lowing results were obtained: urine A 4% and urine B 8%.
Statistical analysis
Continuous variables are presented as mean ± standard devia-
tion if normally distributed or median with interquartile range 
if non-normally distributed. Categorical variables are given 
as number and percentage. The normal distribution of each 
continuous variable was verified by the Kolmogorov–Smirnov 
test. Patients’ characteristics were compared according to DGF 
or IGF (DGF group vs IGF group) using Student’s t-test or 
Mann–Whitney test for continuous variables and chi-square test 
or Fisher’s exact test for categorical variables. Urinary NGAL 
concentrations at each time point were compared between the 
DGF and IGF groups by Mann–Whitney test. Receiver operat-
ing characteristic (ROC) analysis was performed to estimate 
the accuracy of urinary NGAL to predict DGF or eGFR ≥60 
mL/min. The area under the ROC curve (AUC) was calculated 
with 95% confidence interval (CI) for patients with complete 
data at T1, T2, T3, and T4. The level of significance was set at 
p<0.05. Statistical analyses were carried out using SAS soft-
ware, version 9.3 (SAS Institute, Cary, NC, USA).
Results
Demographic, clinical, and 
transplant-related parameters of 
renal transplant recipients
From February 2009 to May 2010, 44 consecutive patients 
who received kidney transplantation from deceased donors 
were enrolled in the study. Before transplantation, all patients 
were under chronic dialysis treatment. One patient who 
experienced acute rejection after 7 days from transplant was 
excluded from the analysis. In the overall transplant recipient 
population, 18 patients had DGF (DGF group) and 25 patients 
had immediate recovery of graft function (IGF group). The 
demographic, clinical, and transplant-related features of the 
2 groups are summarized in Table 1.
Age of the patients ranged from 32 to 70 years, with no 
significant differences found between DGF group and IGF 
group. Likewise, the patients with DGF or IGF did not differ 
significantly in terms of donor age, cold ischemia interval, 
and number of HLA mismatches.
The renal transplant recipients with DGF had a longer 
dialysis vintage prior to transplantation as compared with those 
who had an immediate recovery of graft function (p=0.0204).
All the 18 patients in the DGF group had been under 
hemodialysis treatment before undergoing renal transplant, 
whereas 7/25 patients in the IGF group had been under 
peritoneal dialysis. So, chi-square test revealed a significant 
difference in the distribution of dialysis modality between 
the 2 groups (p=0.0303).
In the overall patient population, end-stage renal disease, 
glomerulonephritides (mostly IgA nephropathy), and adult 
polycystic kidney disease were the most frequent primary 
nephropathies. Adult polycystic kidney disease (APDK) was 
more frequent in patients with DGF, while glomerulonephritis 
was more common in the IGF group, although the differences 
were not statistically significant. The length of hospital stay 
was similar in the 2 groups, with no graft rejection episodes 
occurring until the 30th day of follow-up.
Most of the transplant recipients included in the study 
had no posttransplant complications. Hemorrhage occurred 
more frequently in patients with IGF than in those with 
DGF (difference not significant). One patient in the IGF 
Table 1 Demographic and clinical characteristics of patients
Parameters Total 
patients, 
N=43 (%)
DGF 
group, 
n=18 (%)
IGF 
group, 
n=25 (%)
Sex
Male 29 (67.4) 11 (61.1) 18 (72)
Female 14 (32.6) 7 (38.9) 7 (28)
Recipient age, years 54.0±9.6 54.0±8.5 54.0±10.5
Donor age, years 52.0±7.9 53.2±8.1 49.9±12.8
Cold ischemia time, hours 16.8±6.2 17.1±7.3 16.5±8.1
HLA-A, HLA-B, and HLA-DR 
mismatches
3.3±1.2 3.4±1.1 3.2±1.0
Time on dialysis before 
transplant, months
63.5±29.4 75.6±25.2 54.8±29.6*
Dialysis modality 
Hemodialysis 36 (83.7) 18 (100) 18 (72)*
Peritoneal dialysis 7 (16.3) 0 (0) 7 (28)*
Presence of residual diuresis 16 (37.2) 6 (33.3) 10 (40)
Primary nephropathy
Unknown etiology ESRD 14 (32.6) 7 (38.8) 7 (28)
Glomerulonephritis 13 (30.3) 4 (22.2) 9 (36)
APKD 8 (18.6) 4 (22.2) 4 (16)
Cortical or tubular necrosis 1 (2.3) 1 (5.6) 0 (0)
Interstitial nephritis 3 (7) 0 (0) 3 (12)
Nephroangiosclerosis 3 (7) 1 (5.6) 2 (8)
Diabetic nephropathy 1 (2.3) 1 (5.6) 0 (0)
Length of stay in hospital, days 20.8±7.8 18.0±6.2 22.2±10.0
Complication rate
Hemorrhage 4 (9.3) 1 (5.6) 3 (12.0)*
Urinary fistula 1 (2.3) 0 (0) 1 (4.0)
Abdominal surgery 1 (2.3) 1 (5.6) 0 (0)
None 32 (74.4) 11 (61.1) 21 (84.0)
Notes: Continuous variables are presented as mean ± standard deviation, and 
categorical variables as number (percentage). DGF group and IGF group were 
compared using Student’s t-test for continuous variables and chi-square test for 
categorical variables. *p<0.05.
Abbreviations: APKD, adult polycystic kidney disease; DGF, delayed graft 
function; ESRD, end-stage renal disease; IGF, immediate graft function; HLA, human 
leukocyte antigen.
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group had urinary fistula and 1 in the DGF group needed 
abdominal surgery.
NGAL measurements
Table 2 shows the urinary NGAL levels in patients in 
DGF group and IGF group over time (on the day before 
 transplantation and at days 1, 3, 7, 14, and 30 after 
 transplantation, indicated as T0, T1, T2, T3, T4, and T5, 
respectively). Since the data were non-normally distributed, 
the values are given as median with interquartile range.
Urinary NGAL concentrations progressively decreased 
after transplant in both groups of renal transplant recipients. 
However, in patients with IGF, NGAL levels showed a more 
rapid decrease within 3 days after transplantation. In DGF 
patients, NGAL concentration remained significantly higher 
at 14 days after transplantation, and then progressively 
decreased until the 30th day.
Table 2 Urinary neutrophil gelatinase-associated lipocalin in 
DGF group versus IGF group
DGF group, n=18 IGF group, n=25 p-Value
T0 380.7 pg/mL (280.5–396.9),  
n=6
684.2 (302.1–969.4),  
n=10
ns
T1 594.2 pg/mL (295.4–1212.2),  
n=12
289.2 (71.9–556.1),  
n=23
ns
T2 491.1 pg/mL (197.1–817.8),  
n=16
107.6 (44.5–197.7),  
n=22
0.0022
T3 227.8 pg/mL (118.9–472.8),  
n=16
63.8 (31.1–96.5),  
n=20
0.0025
T4 105.6 pg/mL (33.6–299.4),  
n=15
33.4 (21.0–60.0),  
n=19
0.0244
T5 31.6 pg/mL (18.6–111.2),  
n=13
55.7 (20.5–140.4),  
n=16
ns
Notes: Data are presented as median with IQR. DGF group and IGF group were 
compared using Mann–Whitney test. T0, day before transplant; T1, day 1 after 
transplant;  T2, day 3 after transplant; T3, day 7 after transplant;  T4, day 14 after 
transplant; T5, day 30 after transplant.
Abbreviations: DGF, delayed graft function; IGF, immediate graft function; IQR, 
interquartile range; ns, not significant.
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Figure 1 Mean eGFR values and median levels of urinary NGAL at T0, T1, T2, T3, T4, and T5 in the overall population (A), in patients with DGF (B) and in those with IGF (C).
Note: T0, day before transplant; T1, day 1 after transplant; T2, day 3 after transplant; T3, day 7 after transplant; T4, day 14 after transplant; T5, day 30 after transplant.
Abbreviations: DGF, delayed graft function; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation); IGF, 
immediate graft function; NGAL, neutrophil gelatinase-associated lipocalin; uNGAL, urinary NGAL.
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The AUC showed that the ability of urinary NGAL to 
predict DGF was accurate at the 1st (AUC = 0.70; 95% 
CI: 0.48–0.92), 3rd (AUC = 0.79; 95% CI: 0.58–0.99), 7th 
(AUC = 0.78; 95% CI: 0.58–0.98), and 14th (AUC = 0.72; 
95% CI: 0.52–0.92) days after transplantation.
After 2 years of follow-up, eGFR was evaluated based 
on the CKD-EPI equation. Figure 1 reports the changes 
over time in the median levels of urinary NGAL and the 
mean eGFR in the overall population (Figure 1A), in the 
patients with DGF (Figure 1B), and in those with IGF 
(Figure 1C). Figure 2 shows the cumulative AUC for 
urinary NGAL levels in relation to eGFR: the cumulative 
urinary NGAL in the first 2 weeks after transplant was 
found to be able to predict eGFR ≥60 mL/min in patients 
who experienced DGF.
Discussion
This prospective observational study reports the experience 
of a single Italian kidney transplant center in the investiga-
tion of urinary NGAL as a potential biomarker of DGF in 
renal transplant recipients. Our results showed a progressive 
decline in urinary NGAL concentration over time until the 
end of the 1-month observation period following transplanta-
tion, but the rate of the decrease was significantly slower in 
patients with DGF. The measurement of cumulative urinary 
NGAL concentration for 14 days during hospitalization was 
found to be a valuable predictor of DGF. Moreover, after 2 
years from transplant, the AUC of urinary NGAL in relation 
to graft function indicated a relationship between NGAL 
concentration and eGFR >60 mL/min in those patients who 
had experienced DGF.
NGAL has been described as a promising biomarker in a 
variety of renal and nonrenal conditions, and is routinely used 
for early diagnosis, predicting disease severity and clinical 
outcomes, and therapeutic monitoring.14,18 A previous report 
from our group described the ability of serum and urinary 
NGAL to predict renal function in the first weeks of life 
of preterm infants with a very low birth weight. We found 
that urinary NGAL was significantly higher in infants who 
suffered impaired renal function than in healthy controls.15 
In adults, NGAL is a biomarker for acute renal injury16 
and it is useful to evaluate the risk of DGF after kidney 
transplantation.9,10
NGAL increase occurs rapidly after acute injury, and is 
detectable within a few hours, characterizing NGAL as a 
troponin-like molecule for an early and sensitive reflection 
of kidney function, better than serum creatinine. It has been 
reported that the kidney epithelia express and excrete large 
quantities of NGAL into urine following stress by acute 
injury, reaching up to 1000-fold induction in the most severe 
cases; thus, normalization for urinary creatinine level is not 
mandatory.19
Among the variety of assays and platforms currently 
available for the measurement of NGAL in both urine 
and blood, the ones that may be applied for a diagnostic 
use should be rapid and able to provide the results in <1 
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Figure 2 Cumulative area under the ROC curve for urinary neutrophil gelatinase-associated lipocalin levels measured at T1, T2, T3, T4 and T5 (day before transplant, and 
and days 1, 3, 7, 14, and 30 after transplant), for predicting eGFR ≥60 mL/min. (A) DGF group (n=18; AUC = 0.72; 95% CI: 0.41–1.00); (B) IGF group (n=25; AUC = 0.43; 
95% CI: 0.00–0.86).
Note: T0, day before transplant; T1, day 1 after transplant; T2, day 3 after transplant; T3, day 7 after transplant; T4, day 14 after transplant; T5, day 30 after transplant.
Abbreviations: AUC, area under the curve; CI, confidence interval; DGF, delayed graft function; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease 
Epidemiology Collaboration [CKD-EPI] equation); IGF, immediate graft function; ROC, receiver operating characteristic.
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hour. In this study, we have measured urinary NGAL 
using an ELISA test, which represents a suitable choice 
for research purposes owing to the high sensitivity and 
reliability of this technique. However, this approach is 
less applicable in routine clinical practice when an early 
and timely diagnosis is required, because it does not run 
on automated clinical chemistry analyzers and is more 
time consuming and expensive (about EUR 27/test) than 
the other available assays.
Most of the patients in our population showed elevated 
urinary NGAL levels before transplant, possibly related to 
the chronic inflammatory status established by the previ-
ous dialysis treatment. Although the role of NGAL in 
dialyzed patients is less clear, Malyszko et al showed that 
both urinary and serum NGAL are able to predict CKD 
progression and are related to residual renal function, type 
of renal replacement therapy, and inflammation.20 We found 
similar levels of pretransplant urinary NGAL in patients 
with DGF and IGF, likely due to high variability in their 
clinical history and status. However, the curves of urinary 
NGAL reduction were different between the 2 groups. 
In IGF patients, the NGAL rapidly decreased to levels 
below 200 ng/mL, showing the most prominent reduc-
tion within the first 3 days and then reaching a plateau. 
In DGF patients, urinary NGAL levels remained high for 
several days and dropped concomitantly to DGF resolu-
tion. Therefore, it appears that the rate of NGAL decrease, 
rather than its absolute value, seems to predict DGF, as 
previously reported.21 Furthermore, we demonstrated that 
the measurement of cumulative NGAL concentrations 1 
month after transplant was able to predict poor GFR at 2 
years of follow-up.
The main limitation of the study was the low number of 
patients enrolled. Further larger studies may better define 
the clinical and predictive role of urinary NGAL in DGF 
onset. In this study, we observed that an increased or con-
stantly high NGAL concentration during early monitoring 
after kidney transplant may indicate an extended injury 
with worse prognosis. Therefore, it seems to be useful 
to follow NGAL levels at least 1 month after transplant 
to identify the patients who might potentially experience 
long-term complications of DGF, including longer length 
of hospital stay, higher incidence of acute rejection, and 
poorer long-term graft survival.1,2,22,23 A diagnostic test, 
such as urinary NGAL, that may predict DGF early could 
allow a better management of transplant patients in both 
short- and long-term settings.
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